# TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

> **NCT03123393** · PHASE2 · TERMINATED · sponsor: **Calithera Biosciences, Inc** · enrollment: 49 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** TAK-659

## Key facts

- **NCT ID:** NCT03123393
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-10
- **Primary completion:** 2019-12-17
- **Final completion:** 2019-12-17
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Lack of efficacy of the drug; no safety concern
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123393, "TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03123393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*